Schonfeld Strategic Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$941K	Sell	101,110 -60,872	-38%	-$530K	0.01%	1126
2025 Q4	$1.21M	Sell	161,982 -17,093	-10%	-$173K	0.01%	1051
2025 Q3	$1.56M	Buy	+179,075	New	+$1.07M	0.01%	1167
2024 Q3	–	Sell	-14,273	Closed	-$300K	–	2154
2024 Q2	$300K	Buy	+14,273	New	+$358K	﹤0.01%	1688
2022 Q4	–	Sell	-11,100	Closed	-$89K	–	2718
2022 Q3	$89K	Sell	11,100 -18,200	-62%	-$165K	﹤0.01%	2578
2022 Q2	$205K	Buy	+29,300	New	+$285K	﹤0.01%	1868

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Schonfeld Strategic Advisors's FDMT Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its 4D Molecular Therapeutics (FDMT) stake by 38% in Q1 2026, selling an estimated $530K and leaving 101,110 shares worth $941K. The position accounts for 0.01% of the portfolio, ranked #1126.

Schonfeld Strategic Advisors first reported a position in FDMT in Q2 2022 and has held it in 6 quarters since. The position peaked at $1.56M in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Schonfeld Strategic Advisors held 101,110 shares of 4D Molecular Therapeutics worth $941K as of Q1 2026.
Schonfeld Strategic Advisors sold 60,872 4D Molecular Therapeutics shares in Q1 2026, an estimated $530K.
4D Molecular Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1126 holding.
Schonfeld Strategic Advisors first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's 4D Molecular Therapeutics position peaked at $1.56M in Q3 2025.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.